STADA Arzneimittel AG Logo

STADA Arzneimittel AG

A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.

SAZ | HM

Overview

Corporate Details

ISIN(s):
DE0007251803 (+1 more)
LEI:
529900FMTTLMH0P0DL10
Country:
Germany
Address:
Stadastraße 2 - 18, 61118 Bad Vilbel
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

STADA Arzneimittel AG is a global pharmaceutical company operating with a three-pillar strategy consisting of Generics, Consumer Healthcare, and Specialty Pharmaceuticals. The company is a leading European player in its core segments, ranking as the fourth-largest manufacturer of both generics and consumer healthcare products. Its Generics division focuses on providing affordable medicines. The Consumer Healthcare business is driven by a portfolio of strong regional and 'Local Hero' brands. The Specialty Pharmaceuticals segment develops and markets innovative treatments for specific conditions, including biologic therapies. With a heritage rooted in pharmacies and dating back to 1895, STADA's purpose is to be a trusted partner in caring for people's health.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-20 00:00
Post-Annual General Meeting Information
Datum:20.08.2025
German 9.6 KB
2025-08-11 00:00
Annual Report
Datum:11.08.2025
German 2.2 MB
2025-07-07 00:00
Post-Annual General Meeting Information
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 5.6 KB
2025-02-04 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 564.0 KB
2025-01-21 00:00
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 1.8 MB
2024-02-14 00:00
Annual Report
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 536.7 KB
2024-01-10 00:00
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 1.5 MB
2023-02-23 14:15
Report Publication Announcement
English 3.9 KB
2023-02-23 11:25
Report Publication Announcement
English 4.0 KB
2023-02-23 00:00
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2022 bis zum 31.12.2022
German 5.7 KB
2023-02-23 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
German 5.7 KB
2022-09-27 00:00
Annual / Quarterly Financial Statement
Ergänzung der Veröffentlichung vom 12.04.2022
German 2.2 KB
2022-08-17 09:49
Report Publication Announcement
English 4.0 KB
2022-08-17 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2022 bis zum 30.06.2022
German 5.7 KB
2022-05-10 00:00
Regulatory News Service
Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
German 911.5 KB

Automate Your Workflow. Get a real-time feed of all STADA Arzneimittel AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for STADA Arzneimittel AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for STADA Arzneimittel AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR
ESSA Pharma Inc. Logo
Develops novel small molecule drugs to treat castration-resistant prostate cancer.
United States of America
EPIX
Estrella Immunopharma, Inc. Logo
Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.
United States of America
ESLA
Eton Pharmaceuticals, Inc. Logo
Develops and commercializes innovative treatments for rare pediatric diseases.
United States of America
ETON
EuBiologics Co., Ltd. Logo
Develops vaccines for global public health and provides biopharmaceutical CRMO services.
South Korea
206650
EUPRAXIA PHARMACEUTICALS INC. Logo
Developing targeted, extended-release therapies for GI and musculoskeletal diseases.
United States of America
EPRX
EuroAPI Logo
Global manufacturer of APIs and CDMO services for human and animal health partners worldwide.
France
EAPI

Talk to a Data Expert

Have a question? We'll get back to you promptly.